Shares of Teva Pharmaceutical Industries Ltd. (TEVA) have gained 2.9% over the past four weeks to close the last trading session at $18.25, but there could still be a solid upside left in the ...

In the latest quarter, 4 analysts provided ratings for Teva Pharmaceutical Indus (NYSE:TEVA), showcasing a mix of bullish and bearish perspectives. The table below provides a snapshot of their ...

In the latest quarter, 4 analysts provided ratings for Teva Pharmaceutical Indus TEVA, showcasing a mix of bullish and bearish perspectives. The table below provides a snapshot of their recent ...

Teva gets a buy rating as it trades well below 10-year highs and shows growth potential as the leading global generic drugmaker. Their drug pipeline is robust and diverse, as well as existing ...

Barclays raised the firm’s price target on Teva (TEVA) to $25 from $22 and keeps an Overweight rating on the shares. The firm introduced Olanzapine into its model, noting TEV-749’s sales ...

Teva Pharmaceutical Industries (NYSE:TEVA) and Alvotech (NASDAQ:ALVO) said the FDA has expanded labeling for its biosimilar of Johnson & Johnson’s (JNJ) Stelara to include the treatment of Crohn ...

MADERA, Calif. (KSEE/KGPE) – A Madera businessman is working to reopen the Madera Community Hospital after it closed in 2022. It’s the only hospital in nearly a 30-mile radius, so residents ...